Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda To Merge Units In Ireland, Start Sole Marketing In Portugal

This article was originally published in PharmAsia News

Executive Summary

As a part of a move to strengthen its global production, Takeda Pharmaceutical will merge its two Irish subsidiaries in July. Takeda Ireland is the company's tablet factory and is manufacturing products such as Blopress (candesartan), Actos (pioglitazone) and Prevacid (lansoprazole) for the European and U.S. markets. Takeda Pharma Ireland is Takeda's active pharmaceutical ingredient factory and produces API for insomnia drug Rozerem (ramelteon). Takeda's move is to cut costs and boost efficiency by combining the two units as well as enable it to expand its European market for Actos. The company will start sole marketing operations in Portugal through subsidiary Takeda Portugal. Actos has been marketed as Glustin in Portugal since September 2008 through wholesalers. Takeda said it will buy back from Eli Lilly licensing rights for Actos in Canada and most of Europe. (Click here for more - Japanese language

You may also be interested in...



Biogen’s Big Day Arrives, But Aducanumab Results Don’t Answer Key Question

Biogen presented highly anticipated data in Alzheimer’s disease at CTAD for its Phase III EMERGE and ENGAGE studies, but one major question remains unanswered: will the FDA approve the drug? 

Biogen’s Big Day Arrives, But Aducanumab Results Don’t Answer Key Question

Biogen presented highly anticipated data in Alzheimer’s disease at CTAD for its Phase III EMERGE and ENGAGE studies, but one major question remains unanswered: will the FDA approve the drug? 

Sage Still Sees Approval Path After Depression Drug Fails In Phase III Trial

Sage Therapeutics points to patient compliance and selection as factors in its failed trial of SAGE-217. The company sees positive implications in the data as it waits for other SAGE-217 studies. 

UsernamePublicRestriction

Register

SC071596

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel